-
Innovation Ranking
NewInnovation Ranking – Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE...
-
Product Insights
NewNet Present Value Model: Actinium Pharmaceuticals Inc’s Iomab B
Empower your strategies with our Net Present Value Model: Actinium Pharmaceuticals Inc's Iomab B report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Refractory Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Relapsed Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Net Present Value Model: Actinium Pharmaceuticals Inc’s Actimab-A
Empower your strategies with our Net Present Value Model: Actinium Pharmaceuticals Inc's Actimab-A report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ITM-22 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ITM-22 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ITM-22 in Prostate Cancer Drug Details: ITM-22 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pelgifatamab in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelgifatamab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelgifatamab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-817 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...